Key highlights for Themis Medicare Ltd (NSE: THEMISMED, BSE: 530199)

1. Company snapshot

- Mid-sized Indian pharma company, incorporated in 1969 and headquartered in Vapi, Gujarat.

- Engaged in manufacturing both formulations and APIs, with presence in India and exports to 40+ countries.(themismedicare.com)

- Operates 4 manufacturing facilities in India with a nationwide distribution network of ~4,000 stockists.(themismedicare.com)

2. Business profile

- Therapy focus areas include anti-tuberculosis, anti-malarial, pain management/analgesics, anti-cholesterol, and antiseptics.(screener.in)

- Strategic emphasis on sterile formulations and injectables, complex generics and drug-delivery systems in recent years, often in collaboration with partners like Gedeon Richter.(themismedicare.com)

3. Recent financial performance (FY26 and Q4FY26)

- Q4FY26 (consolidated):

- Revenue from operations ~₹76.5 crore, up ~6.7% YoY but down ~15% QoQ.

- PAT ~₹8.9 crore, a turnaround from a loss in Q4FY25; sequentially lower than Q3FY26.(icicidirect.com)

- FY26 (consolidated):

- Revenue from operations ~₹342 crore, down ~15.6% YoY versus FY25 (~₹406 crore).(icicidirect.com)

- Profitability metrics (ROE/ROCE) have weakened materially in the recent period, with low or near-zero returns reported on some portals, indicating subdued earnings on the current equity base.(stockanalysis.com)

4. Valuation & stock-level data (indicative)

- Recent close: around ₹119 per share on 3 July 2026 (not today’s live price; please re-check on NSE/BSE/your broker).(screener.in)

- Approximate market cap near ₹1,100 crore at that price level.(screener.in)

- 52-week range roughly ₹65 – ₹148, indicating high volatility over the last year.(screener.in)

- Because trailing earnings are depressed/volatile, reported P/E on some sites appears abnormally high or not meaningful; analysis should focus more on normalised earnings and cash flows than on simple trailing P/E.(stockanalysis.com)

5. Balance sheet and quality indicators

- Moderately leveraged: debt-to-equity around 0.25, with a current ratio ~1.8 (not overly stressed on liquidity, but not debt-free).(stockanalysis.com)

- Working capital quality is a watch point; some screeners highlight high receivable days and low interest coverage.(screener.in)

6. Shareholding pattern (broad)

- Promoter holding around 67%.

- Very low institutional participation so far (FIIs/DIIs minimal).

- Balance largely held by retail and other non-institutional investors.(choiceindia.com)

7. Key positives (analytical points, not a recommendation)

- Established brand in select therapies like anti-TB and pain management with long operating history.(screener.in)

- Increasing focus on injectables and complex generics, which can be higher-margin niches if executed well.(themismedicare.com)

- Promoter holding is relatively high, which can align long-term interests.(choiceindia.com)

8. Key risks / monitorables

- FY26 saw a double-digit decline in revenue vs FY25; sustaining growth and regaining operating leverage is critical.(icicidirect.com)

- Return ratios (ROE, ROCE) are currently weak; any investment thesis would typically require visibility of margin improvement and better asset turns.(stockanalysis.com)

- Limited institutional ownership can mean lower liquidity and higher volatility, especially in adverse market phases.(choiceindia.com)

This is a factual highlight and not investment advice. For any investment decision, you should review detailed financials (annual report, quarterly results, and notes) and consider your own risk profile or consult a SEBI-registered investment advisor.

If you have any further queries, please connect with us on 022-6290-10141 (Timings : 09.00 AM to 05.00 PM) or you can email us on info@cniinfoxchange.com